

The constipation illness

GABRIELE BAZZOCCHI, MIMOSA BALLONI

NeuroGastroenterology and Intestinal Rehabilitation Unit, Montecatone Institute Imola / Bologna, Italy

Abstract: Constipation is commonly described as a variety of symptoms including infrequent bowel movements and/or rectal evacuation disorders. Hard stools, excessive straining, bloating and abdominal pain are frequently associated. The several clinical pictures resulting by their combination are mostly due to a primary disturbance of colonic propulsion and/or obstructed rectal emptying, but the chronicity of these initially functional disturbances induce structural changes in the recto-colonic tract (such as dilatation, dolico-colon, rectal prolapse, rectocele, hemorrhoids): constipation turns so in a condition of illness where primary and secondary disorders, functional and organic alterations are not no more clearly detachable and therapeutic priorities are a real challenge for primary care physicians and specialists. The recent knowledges indicate a pivotal role for the gut microbiota in the pathophysiology of colonic dysfunction underlying constipation, contributing to make it a real “systemic” illness, and not a disorder of an organ, given that the impressive consequences which intestinal dysbiosis has on the Enteric, Autonomic and Central Nervous Systems.

Keywords: Chronic constipation; Intestinal microbiota; Colonic motility; Fecal microbiota transplantation

DEFINITION AND CLINICAL PICTURE

Constipation is traditionally defined as a symptom, not a disease, but today it is preferred to define it as a condition of suffering, an illness, a set of symptoms and clinical signs, which the patient can arrive in several ways to^{1,2}. These ways are very different between themselves, but all of them converge towards a precise Syndrome defined by two clinical pictures. The first is characterized by a rarity and a reduced perception of the evacuative stimulus, followed by an easy defecation, after all satisfactory, even if frequently with the expulsion of small and hard stools. Apart from the long interval between two defecations, however spontaneous and normal, there are no other disorders, which clearly distinguishes this form of constipation from the symptomatic disorders that are typical of Irritable Bowel Syndrome (IBS): abdominal pain, swelling and abdominal distension, loss of appetite, difficult digestion and discomfort^{3,4}.

The second “scenario” of constipation is instead characterized by a remarkable association of symptoms: first of all a difficult expulsion, with the perception of an obstacle to the discharge of stools, for which an intense “strain” and need to exercise an excessive abdominal pressure are required. Moreover, sometimes manual maneuvers for supporting stool expulsion are necessary, often with a residual sensation of not having completed bowel emptying. Although this is even more true if stools are scarce and hard, this picture may be present even if the fecal consistency is regular or even fluid. The two clinical pictures often succeed one another, usually the latter is added over time to the first, or they add up and alternate in the short term, creating the most diverse and complicated situations, also in relation to therapeutic attempts (laxatives, drugs, supplements, diets, etc.) which are carried out by patients⁵.

These altered defecation dynamics, the first identified as *Slow Transit Constipation* (STC), the second as *Disordered Defecation* (DD), are then associated with all those conditions that define IBS, above mentioned, in a way that a certain clinical and consequently pathophysiological distinction between the two pathological syndromes, constipation and IBS, is neither possible nor useful for therapeutic purposes. Further symptoms and signs may be associated, such as evidence of abnormal shape and stool (thin, “blocky”, fragmented, smelly), perineal pain, evidence of rectal prolapse or bleeding during and/or after defecation. It should also be considered that these two forms of constipation are further complicated by wrong patient behaviors rather than intestinal dysfunctions: people who think that defecation should be forced after lack of perception of the urge to evac-

uate for 48, 36, or even only 24 hours, use a whole series of measures to induce it (laxatives ingestion; positioning on the toilet trying to expel feces; introduction of suppositories or enemas), thus upsetting what would otherwise have been a regular interval between a spontaneous defecation and the next one. Other people would like to confine defecation at certain times of the day, when toilet is available at home, so that it does not happen during office hours, or for similar reasons: they position themselves on the toilet without having perceived any “need to evacuation” feeling, and “try” to defecate. In the very likely event of a failure or a shortage of intestinal emptying, they seek for treatment because they consider themselves suffering from constipation. This behavior is very often adopted to try to reduce bloating, meteorism or abdominal distension. It is clear that these behaviors, alone or superimposed on a real existing STC or DD, create such complex clinical pictures that their analysis requires an anamnestic investigation, mostly incompatible with the normal times of a medical examination, even in a specialized context. However, the lack of understanding of all the dynamics underlying the condition of constipation reported to the doctor, almost invariably affects the effectiveness of any treatment, even a surgical one, that is prescribed.

ETIOLOGY

As far as the etiopathogenesis of constipation is concerned, it is advisable to immediately clear the field of those situations where evacuation disorders are secondary to an intestinal disease whose onset may occur also, or only, with these conditions: tumors, complications of Diverticular Disease, inflammatory colitis, Celiac Disease and other pathological entities. The suspicion that bowel disturbances are a consequence of these pathologies may easily arise because, in addition to constipation, other symptoms and clinical signs, defined as “alarm features” are present, such as anemization, weight loss, stool blood in absence of anal pathologies, asthenia, fever, and alterations in laboratory test. “Acute” constipation, which suddenly appears in individuals with earlier regular and satisfactory evacuation habits, should be managed as potentially secondary to the above causes and therefore an appropriate diagnostic investigation should be performed⁶. Even when constipation is chronic, it may be secondary to other pathologies, first of all to drug consumption. The intake of opioids, calcium antagonists, adrenergic agonists, dopaminergics, tricyclic antidepressants, neuroleptics and chemotherapeutic agents is often burdened by the progressive appearance of defecation disorders. Moreover, metabolic and hormonal disorders (hypercalcemia,

hypotassiemia, etc.) can cause constipation. The role of neurological pathologies is also very important: severe constipation can easily be classified as a consequence of a spinal or brain injury, due to trauma, hemorrhage, inflammation, and more⁷. On the contrary, other neurological diseases can be the basis of constipation in a decidedly more subtle way: it is not so rare to find of a pathology such as Spina Bifida occulta, tethered cord syndrome and, more generally, pathologies of the cauda equina and sacral region (e.g. Currarino syndrome) after years and years during which the patient, as a rule in the pediatric age, but, from personal experience, even in adult age, reported a constipation which was particularly severe and refractory to any treatment^{8,9}. The appearance of constipation in young women can be for many years the first and only disorder of Multiple Sclerosis, a disease that is then recognized when the typical neurological symptoms appear or are associated with disorders of a “neurogenic bladder”: retention and/or urinary incontinence¹⁰. Even the great neurodegenerative diseases such as Parkinson’s or Alzheimer’s are almost invariably characterized by constipation, both with aspects of STC and DD^{11,12}. It should not be forgotten that diseases of the nerve ganglia of the intestinal wall, such as the congenital Hirschsprung’s disease and the Idiopathic Intestinal Pseudo-obstruction (which instead arises later in life), may cause defecation disorders which are sometimes really difficult to identify. However, all forms due to a clearly identifiable etiology represent a minority of all constipation pictures: in order to have exact percentages, a distinction by age, sex and comorbidity should be performed, which goes beyond the objectives of this article. Anyway, there is consensus that in most cases constipation does not have a known cause, therefore it is classified as primitive or, better, as Functional Constipation, where “functional” means that an intestinal dysfunction is present and, at least at the current state of knowledge, it cannot be related to a verifiable anatomic-pathological picture, or to “markers” of morphological or biochemical alterations affecting the digestive tract or other organs³. However, there are precise observations that even in these forms it is possible to find anomalies, either structural that concern the cellular composition of the Enteric Nervous System (ENS), or neuro-humoral such as alterations of neuromediators and substances that influence the regulation of the motility of the colorectal colon: the problem is, however, that anomalies are never present in all forms of functional constipation, so that, on the one hand, the number of those with unknown etiopathogenesis is narrowed, and, on the other hand, it is possible to state that constipation is a Syndrome, almost never a Disease, but certainly an Illness.

PATHOPHYSIOLOGY

Constipation is always a consequence of a dysfunction of the colon and rectum, given the transit time in the stomach and small intestine is measured in hours, compared to that in the large intestine in days. In a nutshell, we can identify two mechanisms that characterize the dysfunction of the colon at the basis of constipation: on the one hand a deficit, an inefficient propulsive motility of the colon that provides mixing and transport of endoluminal contents (gas and fecal material) and ensures the cyclic filling of the rectum - let’s call it *colonic dysmotility*; on the other hand, an alteration of the complex sensory-motor dynamics that presides over the complete emptying of rectum, sigmoid and descending colon, which we call *obstructed defecation*. The Central Nervous System (CNS) acts in the modulation of both mechanisms. Colonic dysmotility involves the *Autonomic Nervous System (ANS)*, the Enteric Nervous System (ENS) and the smooth muscle of the colon, while the efficiency of

evacuation is guaranteed by the peripheral somatic innervation of the striated diaphragm musculature, the abdominal wall, the pelvic floor including its myo-fascial structure and the anal sphincters.

Colonic Dysmotility is characterized by the reduction/absence of peristaltic contractions with propulsive effect of the colon: recent studies have found alterations of the complex regulation mechanisms of the ENS, a real “second brain” that is located in the intestinal wall and whose complexity, for the number of neurons and integrations between them, is comparable to the brain¹³. Technical and ethical difficulties prevent us from conducting studies on healthy and sick people to understand the relationships between the anomalies identified in ENS functioning, and the behavior of contractility of the bowel muscles seen in patients with constipation, but there is no doubt that the abnormal transport of the endoluminal content through the colon, which is often long and twisted, plays a causal role in many constipations¹⁴⁻¹⁷. Only recently, thanks to the works by the Australian group directed by the physiologist Marcello Costa, it has been possible to understand that propulsion in the large bowel is consequence of two neural mechanisms. The first is the content-independent spontaneous colonic migrating motor complexes that occurs cyclically. The second is a content-dependent, adaptable mechanism controlled by the mechanical activation of enteric neural activity. Mechanosensory enteric neurons (located in the myenteric plexus) have essential mechanosensitive nerve endings in the circular muscle. Distension or stretch of the colon activates these sensory neurons to initiate polarized neural pathways that result in oral contraction and anal relaxation. These pathways do not require the mucosa but can be modulated by sensory nerve endings that project into the mucosa¹⁸. Enteric neural circuitry can efficiently propel content with a wide range of physical properties. This content-dependent activity can be modified in terms of force of contraction and speed of propulsion depending upon consistency and volume of the colonic contents¹⁹. In other words, bolus size and its consistency affects propulsion speed suggesting that propulsion is not a simple reflex, according to the classic theory about intestinal peristalsis²⁰, but rather a more complex process involving an adaptable neuromechanical loop²¹. Consistency depends on the degree of fluidity of the intraluminal colonic contents, which in turn depends on the degree of absorption of fluids along the gut. But consistency is due also by the dry-component of the formed stools, and this is for the 60-80% composed by alive microbial cells originating from the microbiota that dwell in the colon²².

Based on recent revised estimates, the *human microbiota* comprises approximately 10¹³ prokaryotes (bacteria and archaea), as well as fungi and viruses with a contribution of 0.5 kg of the average adult’s body weight, but with an extraordinary metabolic capacity, far exceeding that of human beings²³⁻²⁶. Of all these microbial components, bacteria have been the most thoroughly studied, but it is become increasingly clear that trans-kingdom interactions are just as important in influencing health and disease²⁷. Many if not all human cell structures coexist with a more or less rich microbiota: organs as the lung, or the bladder, not to mention the fetus, which until a few years ago were considered examples of “sterile structures and systems”, in fact turned out to have their own microbiota, and in many cases some of their pathologies have been associated with alterations of its composition. That applies for example to all recent works that describe the role of urinary microbiota in urinary tract and gynecological dysfunction²⁸⁻³⁰. Not discounting a number of shortcomings in the available studies, even blood does not seem to be excluded³¹, whereas the only exception,

to date, is represented by the CNS. There is no doubt, however, that the microbiota residing in our gastrointestinal tract is the hub upon which the modulation not only of all intestinal functions, but also of other organs, depends, including the CNS, even at the level of its “higher” functions such as mood and ideation. Harboring around 10-100 trillion prokaryotic cells at density of 10^{11} to 10^{12} cells/mL, the human gastrointestinal tract is one of the most complex microbial ecosystem on the planet Earth, comprising only a few phyla (Firmicutes and Bacteroidetes) but hundreds of species, thousands of strains, and millions of bacterial genes with specific assemblies for each subject, like fingerprints. Added to this is the high degree of plasticity, i.e. the microbiota ability to change in response to several endogenous and exogenous factors, such as age, diet, geography, lifestyle, intake of drugs and host inflammation³².

So, when a relevant impoverishment of the microbial biomass occurs in the large bowel, that significantly influences colonic propulsion capacity. It should be noted that the action of fibers and prebiotics is not due to a “mass” effect resulting from a recall of water produced by the polysaccharide molecules of which they are made up, but their action, which favors evacuation derives from the fact that they constitute the main metabolic substrate for the colon microbiota, that, as we have seen, the biomass which constitutes the dry weight of the feces³³. Moreover, colonic dismotility may be the direct consequence of intestinal dysbiosis, independently by change in the intraluminal content volume, because function and neuroplasticity of the Enteric Nervous System are influenced directly by colonic microbiota: butyrate may affect neurochemical coding of myenteric neurons and the contractile activity in the rat colon upon long-term exposure. We can speculate that reduced concentration of butyrate in the gut lumen, inducing alterations in cholinergic neurons of myenteric plexus, is only an example among many how colonic motility can be influenced by microbiome imbalance³⁴.

In summary, for the same “contractile” capacity of the bowel, when the content is made up of scarce and fluid fecal material, the efficiency of the oro-aboral transit is profoundly different, if compared to a voluminous content with pasty consistency. It can be said that *an empty colon has no motor activity* and this is very important for explaining many cases of constipation in patients where disturbances of defecation came after profound imbalance in diet habit or antibiotic consumption. Intestinal evacuation, contrary to urination, which is necessary to eliminate metabolic products that would otherwise be harmful and toxic for the body, is nothing but the mechanism, necessary but not sufficient, to maintain a balance of microbiota that dwells and develops in our gut, as a result of a real production process, a sort of “anaerobic bioreactor” contained particularly in the large bowel. It follows that the primary objective of every therapy for constipation is certainly to achieve defecation but not *di per se*, but as a way of rebalancing the ecosystem in the intestinal lumen³⁵. In our study, we demonstrated that in a population of patients with severe functional constipation it was enough to restore a regular colonic content using a symbiotic product for improving defecation disturbances³⁶. An efficient intestinal evacuation requires a total coordination between effort and relaxation of the pelvic floor muscles and anal sphincters. It is not surprising to verify how is frequent a disorder of this area when considering that the ability to control bladder and bowel emptying is the last function that the Homo Sapiens “cub” learns: children start walking and talking before being able of avoiding micturition and defecation at inappropriate times and before diaper weaning. Acquiring this ability means having the encephalic and

medullary centers of both the CNS and the ANS well organized in order to control the same muscle-fascial structures of the abdominal wall and of the pelvic floor, so that they can first be effective at “retaining”, containing urine, feces of various consistency, gas, and then efficient at expelling them at chosen times, thus ensuring a complete emptying.

An *Obstructed Defecation* can derive from a paradoxical contraction of the puborectalis muscle and/or an abdominal-perineal dyssynergia, so that the pressure increase indispensable to expel is not achieved; or it can derive from structural alterations that mechanically hinder the expulsion of fecal content: a bulging of the wall of the rectum (rectocele), a pathological descent of the perineal plane, or a rectal prolapse or intussusception are the conditions that hinder efficient evacuation, sometimes up to completely prevent it. Hence derives the need to “open” the way to the expulsion of fecal content with suppositories, enemas, manual maneuvers and the assumption of particular postures. Continuous vicious circles exist between functional and structural alterations, so that the onset of one worsens the second and so on.

ASSESSMENT

A meticulous clinical history and a proctological evaluation, better if complete with an anoscopy, make it possible, in most cases, to gather all necessary elements for a correct framing of the constipation form. The execution of a rectal exploration, first digital and then with a disposable rectoscope, without any preparatory cleaning, is very useful in these cases because it allows to identify the presence of feces in the rectum: knowing the time from the last evacuation, it can be deduced if the rectal coprostasis is a consequence of incomplete emptying, if this has happened in a short time. Or it can signal a problem of visceral sensitivity if the last evacuation has taken place previously, at a considerable distance, and the presence was not perceived by the patient.

The clinical and anamnestic evaluation is sufficiently precise when the “alarm” symptoms/signs mentioned above are not present. In the presence of one or more signs, a specific clinical and laboratory diagnostic pathway is necessary to exclude the aforementioned pathologies and other possible organic causes of the evacuative disorder.

Other forms of investigation that allow acquiring further elements of distinction between the physiopathological mechanisms at stake in a constipation are certainly the *defecography* and the *ano-rectal manometry*^{4,5,37}. They provide useful elements only if carried out by expert operators and according to specific execution protocols which, unfortunately, are almost never the “standard” ones in Radiology and Gastroenterology units, not dedicated to this pathology. A clear example is the ano-rectal manometry performed with a technique that does not allow recording the pressure increase that occurs in the upper rectum during the abdominal pressure, the evacuative effort. The lack of this element does not allow recognizing and classifying the type of dissynergic defecation³⁸. Other investigations are the rectal balloon expulsion test and the perineal and anal sphincter electromyography, but the same applies: they provide useful elements only in expert hands and when the indication is very clear. Investigations such as the study of the intestinal transit time using radiopaque markers are not of widespread use because their clinical value depends on the technique used, on a documented bowel diary and on the inclusion in a very specific therapeutic program.

PHARMACOLOGIC THERAPIES FOR CONSTIPATION
Supplements, drugs, devices, dietary schemes, behavioral indications, rehabilitation programs, psychological treatments or treatments with water could fill up an endless list.

Perhaps no other condition boasts as many “cures” as constipation. Many of these approaches have never been subjected to a rigorous scientific evaluation, but are spread by word of mouth about constipation therapy and, maybe even more, about desperate search for solution, since defecation disorders, along with scarcity of integrated, competent and dedicated responses by public hospital facilities, may cause such an incredible impairment of Quality of Life².

The medical “arsenal” is very wide, even if restricted to products and devices supported by evidence of effectiveness. Certainly macrogol 3550 or 4000 products are useful: at high doses to resolve “blocks” and important fecal retentions; in small doses to guarantee optimal fecal consistency and easy evacuation^{39,40}. Also the stimulant laxatives are useful: picosulphate, senna products, cascara, etc. may effectively stimulate the propulsion of the colon⁴¹. However, entrusting the solution of constipation exclusively to these drug intake does not make sense, but their use can be beneficial and irreplaceable, when in combination with other strategies. It is difficult to understand why laxatives from herbalist’s shops, markets, or “natural” product stores, are preferred to the products which are proposed by pharmacies and so subjected to strict tests of tolerability, definition of the right dose and reliability of the preparation technique. The alleged “naturalness” of the non-pharmacy product often hides big problems of bioavailability, purity, dose-dependent efficacy, presence of additives and other substances with counterproductive effects.

There are also products based on soluble dietary fiber (psyllium derivatives, glucomannans and many others): the axiom that constipation equals fiber deficiency and, therefore, requires a diet rich in fruit, vegetables and bran supplements, has never been true and is nourished only by common myths⁴², although there is no doubt that these treatments can have positive effects in many forms of constipation, particularly when an impoverishment of colon microbiota occurs so compromising a regular “stool production”, as we have already discussed. The same goes for products based on alive bacteria, the probiotics, and prebiotics such as FOS, inulin and others. Systematic review and meta-analysis still struggle for finding clear evidence of efficacy of probiotics in chronic constipation⁴³, but this may be due to the methodological approach of the studies since the rationale for its benefic action is too strong. The best is probably their combination with other strategies (laxatives, prokinetic drugs). It is already possible to distinguish between the different types of probiotics, mono-strain products and mixtures of various microorganisms, and to define the dose administration and their ability to colonize the digestive tract, according to the pathology, e.g. constipation, diarrhea, inflammatory disease, visceral pain etc.^{44,45}.

Other drugs such as prucalopride, linaclotide, and other more recently available ones, have powerful effects in stimulating peristalsis of the colon with different and more “physiological” mechanisms compared to laxatives⁴⁶⁻⁴⁸. When the constipation is based only on dysmotility, they are undoubtedly useful, while when obstructed defecation and dysbiosis are involved, they cannot solve the situation alone. Moreover, they are often abandoned due to fairly high costs, while they could be effective and decisive in combination with other products, so permitting to reduce them. If oral therapy is ineffective, many people with constipation often use enemas, rectoclysis, or colon hydrotherapy sessions⁴⁹. Even these approaches are often not decisive, but they are undoubtedly useful to remove stagnant contents from the large intestine and to allow the colon to bear a poly-therapy specifically aimed at rebalancing the intestinal microbiota, which, in the early stages, may be burdened by swelling, pain, irregular

evacuation frequency and persistent obstruction symptoms. These disorders lead the patient to suspend therapy before time, since the effects are possibly beneficial, but often unbearable, in the long term. Hence derives the usefulness of guaranteeing an “artificial” evacuation through different Trans Anal Irrigation (TAI) approaches that make use of sophisticated “constant and controlled positive pressure” systems: water is introduced by positive pressure, unlike the atmospheric one (as used for rectoclysis), not intermittently (as for enemas and washing syringes) and adapted to the single patient^{50,51}. TAI with these devices, initially exclusive for patients with forms of constipation secondary to neurological pathologies, is proving to be useful also in the most severe functional forms and in forms arising after destructive operations of the pelvic organs⁵².

WHAT ABOUT DIET, REHABILITATION OF PELVIC FLOOR, BIOFEED-BACK, SURGERY?

Patients are more and more confused about “nutrition”, and so are the therapists who prescribe restrictions that are often unbearable and meaningless. As regards constipation *di per se*, when not associated with the symptoms of other functional diseases, such as Irritable Bowel Syndrome, or allergies and intolerances well documented by laboratory and instrumental tests, the diet regime to follow is the *Mediterranean diet*⁵³. Eliminating components from our traditional diet, for fear of other pathologies (off with harmful fats!) or increasing others in the hope of relieving constipation (eat more fruit and vegetables!) results in an imbalance of the intestinal microbiota and an impoverishment of its richness and stability, with a higher prevalence of certain bacterial groups and pathological consequences, including constipation and abdominal discomfort: whenever this approach could be therapeutic for the same disorders?

Pelvic floor rehabilitation techniques and biofeedback, in experienced hands and for well-selected forms of constipation, are unquestionably useful⁵. The same applies to surgical operations aimed at resolving the pathologies that cause mechanical obstruction to stool passage and expulsion. There is no doubt indication for surgical repair in a woman with a rectal prolapse/intussusception or a large anterior rectocele, which formed over time after difficult childbirths, and after years of food errors and evacuation effort due to hard stools is correct. But also in this case, operation will not be so succeed if not preceded and followed by restoration of normal stool consistency and volume, since hard stools are expression of dysbiosis and dysmotility of the colon, as well as pathological stagnation in the sigmoid due to the incomplete evacuation.

In recent years doubts have arisen over the indication of major surgery, such as total colectomies or extensive resections, without any detailed documentation of ENS alterations. These interventions are usually a *last resort* when previous surgery was not useful.

It is probably too early for including the *Fecal Microbiota Transplantation* (FMT) among the therapeutic options for chronic constipation, even if this approach has been already tested⁵⁴. We have seen that the human gut microbiota is not a mere assembly of microorganisms, but a highly organized integrated network of cells interacting intensely with each other as well as with the host, which could be thought of as an additional organ within the human body. Based on the available literature, the possibility of transferring this *organ* from a healthy individual, i.e. endowed with a high-diverse intestinal microbiota, to an individual whose microbiota is impoverished, unbalanced and unable to oppose the action of pathogens, has proved to be highly effective and statements on FMT indications, donor selection, preparation of

fecal material, clinical management and fecal delivery, and basic requirements for implementing an FMT centre are already well established^{55,56}. The first and most documented clinical application of FMT is recurrent *Clostridium difficile* infections (rCDI) in which it is currently used as a last-resort treatment after failure of multiple courses of antibiotics⁵⁷, but beyond rCDI, FMT has been evaluated as a treatment option in a variety of gastrointestinal diseases, such as Inflammatory Bowel Diseases^{58,59}, non-alcoholic steatohepatitis, alcoholic hepatitis, hepatic encephalopathy^{60,61}. The evidence that FMT can be useful in the treatment of disorders as Irritable Bowel Syndrome⁶² and constipation is very interesting, confirming what we have discussed, i.e. in this disorder intestinal dysbiosis and altered interaction with gut mucosa are pivotal. Moreover, extremely interesting it is that manipulation of gut microbiota through FMT seems to be effective also in conditions outside the GI tract, such as autism and mood disorders⁶³ and the metabolic syndrome⁶⁴. Since it is clear that intestinal dysbiosis may contribute to the pathogenesis of many diseases, FMT is increasingly being explored as a potential treatment that aims to optimize microbiota composition and functionality⁶⁵.

CONCLUSIONS

Constipation, it is a syndromic condition, not life-threatening unlike other diseases of the digestive system, such as cancer, inflammatory diseases, hepatitis, peptic ulcer, etc., but it causes suffering and undermines Quality of Life often more than these. It is common and burdened by entails huge social costs for treatments, examinations, hospitalizations and work capacity impairment, especially in countries with high standards of living. It recognizes a very complex etiopathogenesis in which both underlying pathophysiological mechanisms and therapeutic approaches - that are attempted, assumed and then abandoned, in inextricable cause-effect circles - play an equally important role. Constipation is not considered a significant health problem, so there are no specifically dedicated centers in Italian hospitals. In order to seek solutions, the patient has to contact a specialist, who, even if he/she is the right choice in terms of cultural knowledge and clinical experience, will hardly be able to work with a team that integrates all skills needed for diagnostics and a global approach to the patient with constipation illness.

REFERENCES

- Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. *Alim Pharmacol Ther* 2007; 25: 599-608
- Nellesen D, Yee K, Chavvula A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in Irritable Bowel Syndrome and Chronic Constipation. *J Manag Care Pharm* 2013; 19: 755-764
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology*. 2006; 130: 1480-91.
- Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. *Gastroenterology* 2016; 150: 1393-1407
- Rao SSC, Bharucha AE, Chiarioni G, Felt-Bersma R, Knowles C, Malcom A, Wald A. Anorectal Disorders. *Gastroenterology* 2016; 150: 1430-1442.
- Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SST, Chey W, Simren M, Lembo A, Young-Fadok TM, Chang L. Chronic constipation. *Nature Reviews* 2017; 3: article n 17095
- Bazzocchi G, Shuijt C, Pederzini R, Menarini M. Bowel dysfunction in spinal injury patients: pathophysiology and management. *Pelviperroneology* 2007; 26: 84-87
- Brochard C, Peyronnet B, Dariel A, Menard H, Manunta A, Ropert A, Neunlist M, Bouguen G, Siproudhis L. Bowel dysfunction related to Spina Bifida: keep it simple. *Dis Colon Rectum* 2017; 60: 1209-1214
1. Doolin E. Bowel management for patients with myelodysplasia. *Surg Clin North Am* 2006; 86: 505-514
- Lawthom C, Durdey P, Hughes T. Constipation as a presenting symptom. *Lancet* 2003; 362: 958
- Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce Aj. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 2016; 87: 710-716
- Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. *Cochrane Database Syst Rev* 2014; 13: CD002115
- Avetisyan M, Schill EM, Heuckeroth RO. Building a second brain in the bowel. *J Clin Invest* 2015; 125: 899-907
- Moreno-Osset E, Bazzocchi G, Lo S, Trombley B, Ristow E, Reddy SN, Villanueva-Meyer J, Fain JW, Jing J, Mena I, Snape, Jr, WJ. Association between postprandial changes in colonic intraluminal pressure and transit. *Gastroenterology* 1989; 96: 1265-1273
- Bazzocchi G, Ellis J, Villanueva-Meyer J, Jing J, Reddy SN, Mena I, Snape, Jr, WJ. Postprandial colonic transit and motor activity in chronic constipation. *Gastroenterology* 1990; 98: 686-693
- Bassotti G, deRoberto G, Castellani D, Sediari L, Morelli A. Normal aspects of colorectal motility and abnormalities in slow transit constipation. *World J Gastroenterol* 2005; 11: 2691-2696
- Dinning PG, Wiklendt L, Maslen L, Patton V, Lewis H, Arkwright JW, Wattoo DA, Lubowski DZ et al. Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry. *Neurogastroenterol Motil* 2015; 27: 379-388
- Spencer NJ, Dinning PG, Brookes SJ et al. Insights into the mechanisms underlying colonic motor patterns. *J Physiol* 2016; 594: 4099-4116
- Dinning PG, Wiklendt L, Omari T et al. Neural mechanisms of peristalsis in the isolated rabbit distal colon: a neuromechanical loop hypothesis. *Frontiers Neuroscience* 2014; 8: 1-14
- Tonini M, Spelta V, De Ponti F et al. Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon. *Gastroenterology* 2001; 120: 938-945
- Costa M, Wiklendt L, Simpson P et al. Neuromechanical factors involved in the formation and propulsion of fecal pellets in the guinea-pig colon. *Neurogastroenterol Motil* 2015; 27: 1466-1477
- Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. *Gut* 2016; 65: 57-62.
- Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol* 2016; 14: e1002533.
- Carding SR, Davis N, Hoyles L. Review article: the human intestinal virome in health and disease. *Aliment Pharmacol Ther* 2017; 46: 800-815.
- Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. *Nat Rev Immunol* 2017; 17: 635-646.
- Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. *Cell Metab* 2017; 26: 110-130.
- Owyang C, Wu GD. The Gut microbiome in Health and Disease. *Gastroenterology* 2014; 146: 1433-1436.
- Brubaker L, Wolfe AJ. The new world of the urinary microbiome in women. *Am J Obstet Gynecol* 2015; 213: 644-649.
- Schneeweiss J, Koch M, Umek W. The human urinary microbiome and how it relates to urogynecology. *Int Urogynecol J* 2016; 27: 1307-1312.
- Antunes-Lopes T, Vale L, Coelho AM et al. The role of urinary microbiota in lower urinary tract dysfunction: a systematic review. *Eur Urol Focus* 2018; 27: S2405-4569
- Castillo DJ, Rifkin RF, Cowan DA et al The healthy human blood microbiome: fact or fiction? *Front Cell Infect Microbiol* 2019; 9: 148
- Candela M, Biagi E, Maccaferri S, Turroni S, Brigidi P. Intestinal microbiota is a plastic factor responding to environmental changes. *Trends Microbiol* 2012; 20: 385-91.
- Sant'Anna MSL, Ferreira CLLF. Can intestinal constipation be modulated by prebiotics, probiotics and Symbiotics? *Food and Nutrition Sciences* 2014; 5: 1106-1113.
- De Giorgio R, Blandizzi C. Targeting Enteric Neuroplasticity:

- Diet and Bugs as New Key Factors. *Gastroenterology* 2010; 138: 1663-1666
35. Quigley EMM. The enteric microbiota in the pathogenesis and management of constipation. *Best Practice & Research Clinical Gastroenterol* 2011; 25: 119-126.
 36. Bazzocchi G, Giovannini T, Giussani C et al. Effect of a symbiotic preparation on symptoms, stool consistency, intestinal transit time and gut microbiota in patients with severe functional constipation: a double blind, controlled trial. *Tech Colo- Proctol* 2014; 18: 945-953
 37. Locke GR, Pemberton JH, Phillips SF. American Gastroenterological Association Medical position statement: guidelines to constipation. *Gastroenterology* 2000; 119: 1761-1766
 38. Rao SSC, Patchrarakul T. Diagnosis and treatment of Dyssynergic Defecation. *J Neurogastroenterol Motil* 2016; 22: 423-435.
 39. Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, Lucà MG, Galeazzi R, Peruzzi E. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. *Gut* 2000; 46: 522-526.
 40. Bazzocchi G. Polyethylene glycol solution in subgroups of chronic constipation patients: experience in obstructed defaecation. *Ital J Gastroenterol Hepatol* 1999; 31 (Suppl.3): S257-259.
 41. Parè P, Fedorak RN. Systematic review of stimulant and non-stimulant laxatives for the treatment of functional constipation. *Can J Gastroenterol Hepatol* 2014; 28: 549-557
 42. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. *Am J Gastroenterol* 2005; 100: 232-242
 43. Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moyayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *Am J Gastroenterol* 2014; 109: 1547-1561
 44. Rousseaux C, Thuru X, Gelot A et al. *Lactobacillus acidophilus* modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med* 20017; 13: 35-37.
 45. Kunze WA, Mao YK, Wang B et al. *Lactobacillus reuteri* enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. *J Cell Mol Med* 2009; 13:2261-2270.
 46. Miner Jr PB, Camilleri M, Burton D, Achenbach H, Wan H, Dragone J, Mellgard B. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. *Neurogastroenterol Motil* 2016; 28: 1341-1348
 47. Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D. Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, controlled trial. *Dig Dis Sci* 2016; 61: 852-860
 48. Lembo AJ. Two randomized trials of linaclotide for chronic constipation. *N Engl J Med* 2011; 365: 527-536
 49. Bazzocchi G., Giuberti R. Irrigation, lavage, colonic hydrotherapy: from beauty center to clinic? *Techniques in ColoProctology* 2017; 21: 1-4
 50. Juul T, Christensen P. Prospective evaluation of transanal irrigation for fecal incontinence and constipation. *Tech Coloproctol* 2017; 21: 363-371
 51. Emmanuel AV, Krogh K, Bazzocchi G, Leroi AM, Bremers A, Leder D, van Kuppevelt D, Mosiello G, Vogel M, Perrouin-Verbe B, Coggrave M, Christensen P. Consensus review of best practice of transanal irrigation in adults. *Spinal Cord* 2013; 51: 732-8.
 52. Wilkinson-Smith V, Bharucha AE, Emmanuel A, Knowles C, Yiannakou Y, Corsetti M. When all seems lost: management of refractory constipation-Surgery, rectal irrigation, percutaneous endoscopic colostomy, and more. *Neurogastroenterol Motil* 2018; 30: e13352
 53. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW, Ercolini D. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metaboloma. *Gut* 2016; 65: 1812-1821
 54. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. *J Clin Gastroenterol* 2004; 38: 475-483
 55. Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017; 66: 569-580
 56. Krajcicek E, Fisher M, Allegretti JR, Kelly CR. Nuts and bolts of fecal microbiota transplantation. *Clin Gastroenterol Hepatol* 2019; 17: 345-352
 57. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. *Nat Rev Gastroenterol Hepatol* 2012; 9: 88-96.
 58. Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for the patients with ulcerative colitis. *Gastroenterology* 2015; 149: 110-118.
 59. Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomized placebo-controlled trial. *Lancet* 2017; 389: 1218-118.
 60. Millan B, Laffin M, Madsen K. Fecal Microbiota Transplantation: beyond *Clostridium difficile*. *Curr Infect Dis Rep* 2017; 19: 31
 61. Baja JS, Kassam Z, Fagan A et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. *Hepatology* 2017; 66: 1727-1738
 62. Johnsen PH, Hilpusch F, Cavanagh JP et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-centre trial. *Lancet Gastroenterol Hepatol* 2018; 3: 17-24
 63. Mangiola F, Ianiro G, Franceschi F et al. Gut microbiota in autism and mood disorders. *World J Gastroenterol* 2016; 22: 361-368
 64. Kootte RS, Levin E, Salojarvi J et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metab* 2017; 26: 611-619
 65. Vaughn BP, Rank KM, Khoruts A. Fecal microbiota transplantation: current status in treatment of GI and Liver Disease. *Clin Gastroenterol Hepatol* 2019; 17: 353-361.

Acknowledgments

The Authors are indebted to Dr. Cecilia Baroncini, Scientific Office of the Montecatone Rehabilitation Institute, for the secretarial assistance.

Disclosure

There were no conflicts of interest and the authors of the publication did not receive any financial support by any grant/research sponsor

Correspondence:

Prof. Gabriele Bazzocchi, MD, Ph.D, AGAF
 gabriele.bazzocchi@unibo.it
 Dr. Mimosa Balloni, MD mimosa.balloni@montecatone.com
 NeuroGastroenterology and Intestinal Rehabilitation Unit,
 Montecatone Rehabilitation Institute S.p.A,
 via Montecatone 37 Imola, BO, Italy